Significantly improved chance of heart attack survival with high-potency statin treatment

February 20, 2014 by Roddy Isles, University of Dundee

(Medical Xpress)—A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking normal statins.

The study, led by the University of Dundee, also found a combination of and the drug showed no improved survival rate, although researchers caution this finding needs further testing.

'There is presently a lot of interest in ezetimibe as a potential treatment for heart ,' said Professor Chim Lang, from the Division of Cardiovascular and Diabetes Medicine at the University of Dundee Medical School.

'Ezetimibe has been shown to be very effective at lowering cholesterol but we do not know its effect on survival. The key question really is whether it is better than statins, especially high potency statins such as rosuvastatin or atorvastatin.

'What our study has showed, looking at the data from thousands of patients in the UK, is that patients who switched from normal statin treatment to high potency statins lived longer.

'Those who had ezetimibe added did not appear to have a better outcome. So for the moment the data supports the use of high potency statins, one of which, atorvastatin, is now off patent and is cheap and effective.'

Results of the study have been published online in the journal Heart.

Data for the study was drawn from the UK's Clinical Practice Research Datalink. Researchers looked at the data for patients who had survived 30 days after their first , who had not received prior statin or ezetimibe therapy, and who were started on a statin within that period of their attack.

The data of 9597 patients was used. 6990 of those were treated with simvastatin, 1883 had switched to a more potent statin, and 724 were given an ezetimibe/statin combination.

Data for the group was analysed for an average 3.2 years from the start point of their first attack. During that time there were 1134 deaths.

The results showed that patients who switched to a high-potency statin had a 28% lower risk of death compared to those who received simvastatin. There was no observed benefit of adding ezetimibe.

Explore further: Low-dose statins good option for some heart patients, study finds

Related Stories

Low-dose statins good option for some heart patients, study finds

February 10, 2014
(HealthDay)—A new analysis suggests that people at high risk for heart disease who can't take high-dose statin drugs to lower their cholesterol might benefit from a treatment combination that includes taking a low-dose ...

Elevated cholesterol levels: Benefit of ezetimibe is not proven

September 14, 2011
Elevated blood cholesterol levels are regarded as a risk factor for heart attacks and other cardiovascular diseases. However, this does not necessarily mean that every cholesterol-lowering drug can also prevent heart attacks. ...

High potency statins pose significantly higher risk of kidney injury than low potency, say experts

March 19, 2013
Patients taking high potency statins for high blood pressure are at a 34% higher risk of being hospitalised for acute kidney injury (AKI), compared with those taking low potency statins, a paper published today in BMJ suggests.

Statin use is linked to increased risk of developing diabetes, warn researchers

May 23, 2013
Treatment with high potency statins (especially atorvastatin and simvastatin) may increase the risk of developing diabetes, suggests a paper published today in BMJ.

Early statin therapy helps kids with inherited high cholesterol

November 18, 2013
Children with inherited high levels of cholesterol who receive cholesterol-lowering statins in their early years have a lower risk of coronary heart disease than their affected parents, according to research presented at ...

Statin use reduces delirium in critically ill patients

January 17, 2014
Continued use of statins may help prevent delirium in critically ill patients who received statins before hospital admission, according to a new study of 470 intensive care patients in the UK.

Recommended for you

Novel genetic study sheds new light on risk of heart attack

October 12, 2018
Loss of a protein that regulates mitochondrial function can greatly increase the risk of myocardial infarction (heart attack), Vanderbilt scientists reported Oct. 3 in the journal eLife.

Researchers say ritual for orthodox Jewish men may offer heart benefits

October 11, 2018
A pilot study led by researchers at the University of Cincinnati (UC) College of Medicine suggests Jewish men who practice wearing tefillin, which involves the tight wrapping of an arm with leather banding as part of daily ...

Markers of dairy fat consumption linked to lower risk of type two diabetes

October 10, 2018
Higher levels of biomarkers of dairy fat consumption are associated with a lower risk of developing type 2 diabetes, according to new research published today in PLOS Medicine. The study, in more than 60,000 adults, was undertaken ...

Seed oils are best for LDL cholesterol

October 9, 2018
If you want to lower your low-density lipoprotein cholesterol, called LDL or, colloquially, "bad cholesterol," the research is clear about one thing: You should exchange saturated fats with unsaturated fat. If you want to ...

Micropeptide restores heart function in mice

October 9, 2018
Researchers have discovered a micropeptide molecule that can restore normal heart function in mice, according to a study in eLife.

New risk test for sepsis for heart patients

October 5, 2018
Nearly one in four deaths in people with heart failure are caused by sepsis, according to new research.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.